ZuraBio (ZURA)
Develops licensed antibody candidates for autoimmune and inflammatory diseases.
Something off on this page? Send us feedback.
Develops licensed antibody candidates for autoimmune and inflammatory diseases. The clinical-stage business centers on tibulizumab and depends on global licenses and external development partners.
Develops globally licensed antibody candidates for autoimmune and inflammatory diseases across several distinct programs. The portfolio includes tibulizumab, ZB-168, and torudokimab, with tibulizumab in two Phase 2 studies. With no disclosed product sales, operations center on clinical development rather than commercial product delivery.
Built through licenses from Pfizer and Eli Lilly, the business relies on rights to the underlying patents, know-how, and technology. Its development work also depends on contract development and manufacturing organizations, contract research organizations, and clinical sites. These license agreements and third-party relationships shape how the portfolio advances.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Aug 12, 2026 | Guggenheim | Reiterate | Buy | $15 | $20 |
| Jul 8, 2026 | William Blair | Initiate | Outperform | ||
| Feb 9, 2026 | Wedbush | Target | $15 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $205.1M · Total debt $0 · Total assets $213.4M · Shareholders' equity $197.1M
- Revenue
- $0
- Operating income
- −$29.3M
- Net income
- −$26.3M
No dividends on record.
| Institutions97 holders · as of Mar 31, 2026 | 68.93% | 66.06M shares | |
| Insiders6 holders · as of Jun 22, 2026 | 3.40% | 3.26M shares | |
| Strategic holders1 holder · as of Jan 2, 2026 | 12.09% | 11.58M shares | |
| Otherremainder | 15.58% | 14.93M shares |
95.83M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Athanor CapitalStrategic10 percent owner | 12.09% | 11.58M | Form 4filed Jan 2, 2026 ↗ |
Venrock Healthcare Capital Partners III, L.P.Institution | 10.24% | 9.82M | 13Gfiled May 15, 2026 ↗ |
Suvretta Capital Management, LLCInstitution | 9.46% | 9.07M | 13Fas of Mar 31, 2026 |
VR Adviser, LLCInstitution | 6.72% | 6.43M | 13Fas of Mar 31, 2026 |
JPMorgan Chase & CoInstitution | 4.65% | 4.46M | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Feb 26, 2026 | AI Biotechnology LLC | 10 percent owner | +2,000,000 | $6.25 |
- MoonLake Immunotherapeutics
Phase 3 IL-17A/F Nanobody program in moderate-to-severe HS
- Novartis (ADR)
Approved IL-17A biologic for adult and pediatric HS
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| ZuraBio | $5.72 | +0.79% | $538.6M | — | — | — | — |
| MoonLake Immunotherapeutics | $15.02 | −0.33% | $1.27B | — | — | — | — |
| Novartis (ADR) | $161.86 | −0.36% | $308.79B | 24.5 | 17.3 | 5.6 | +0.9% |
| Median | 24.5 | 17.3 | 5.6 | +0.9% |